Dr. David Sommerhalder

Hematology Oncology | Oncology | Hematology
2829 Babcock Rd, Suite 300, 
San Antonio, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
2829 Babcock Rd, Suite 300, 
San Antonio, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Sommerhalder is a Hematologist Oncology specialist and an Oncologist in San Antonio, Texas. Dr. Sommerhalder is rated as an Experienced provider by MediFind in the treatment of Li-Fraumeni Syndrome. His top areas of expertise are Dehydration, Ovarian Cancer, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, and Orchiectomy. Dr. Sommerhalder is currently accepting new patients.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Hospital Affiliations
Methodist Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

TEXAS ONCOLOGY PA
2829 Babcock Rd, Suite 300, San Antonio, TX 78229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors
A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors
Enrollment Status: Recruiting
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: ABBV-CLS-484, Programmed Cell Death-1 (PD-1) Inhibitor
Study Phase: Phase 1
A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
Enrollment Status: Completed
Publish Date: October 10, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid Tumors
A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: December 12, 2024
Intervention Type: Drug
Study Phase: Phase 1
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
An Open-label Phase 1b Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors
An Open-label Phase 1b Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: December 15, 2023
Intervention Type: Drug
Study Phase: Phase 1
A First-in-Human, Phase 1/2 Study of NBE-002, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors
A First-in-Human, Phase 1/2 Study of NBE-002, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 07, 2023
Intervention Type: Drug
Study Drug: NBE-002
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Enrollment Status: Unknown
Publish Date: October 19, 2021
Intervention Type: Biological
Study Phase: Phase 1
View 6 Less Clinical Trials

9 Total Publications

Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study.
Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study.
Journal: EClinicalMedicine
Published: May 06, 2025
Similar Doctors
Experienced in Li-Fraumeni Syndrome
Dr. Esther Urbaez-Duran
Hematology Oncology | Hematology | Oncology
Experienced in Li-Fraumeni Syndrome
Dr. Esther Urbaez-Duran
Hematology Oncology | Hematology | Oncology

Gmg Health Systems Associates PA

730 Pleasanton Rd, 
San Antonio, TX 
 (10.8 miles away)
210-921-3800
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Esther Urbaez-Duran is a Hematologist Oncology specialist and a Hematologist in San Antonio, Texas. Dr. Urbaez-Duran is rated as an Advanced provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Cryoglobulinemia, Familial Mixed Cryoglobulinemia, Iron Deficiency Anemia, and Thrombocytopenia. Dr. Urbaez-Duran is currently accepting new patients.

Experienced in Li-Fraumeni Syndrome
Dr. Gladys I. Rodriguez
Hematology Oncology | Hematology | Oncology
Experienced in Li-Fraumeni Syndrome
Dr. Gladys I. Rodriguez
Hematology Oncology | Hematology | Oncology

South Texas Oncology And Hematology, PLLC

155 E Sonterra Blvd, Suite 200, 
San Antonio, TX 
 (9.3 miles away)
210-593-5700
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Gladys Rodriguez is a Hematologist Oncology specialist and a Hematologist in San Antonio, Texas. Dr. Rodriguez is rated as an Advanced provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Retroperitoneal Liposarcoma, and Desmoplastic Small Round Cell Tumor. Dr. Rodriguez is currently accepting new patients.

Experienced in Li-Fraumeni Syndrome
Dr. Prathibha A. Surapaneni
Hematology Oncology | Hematology | Oncology
Experienced in Li-Fraumeni Syndrome
Dr. Prathibha A. Surapaneni
Hematology Oncology | Hematology | Oncology

South Texas Oncology And Hematology, PLLC

4383 Medical Dr, 
San Antonio, TX 
 (1.1 miles away)
210-593-5700
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Prathibha Surapaneni is a Hematologist Oncology specialist and a Hematologist in San Antonio, Texas. Dr. Surapaneni is rated as an Experienced provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Angiosarcoma, Paget Disease of the Breast, Breast Cancer, and Inflammatory Breast Cancer. Dr. Surapaneni is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sommerhalder's expertise for a condition
ConditionClose
        View All 33 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile